Search results
Showing 1546 to 1560 of 7707 results
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)
NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia in adults because no evidence submission was received from Pfizer.
Show all sections
Sections for TA576
Ublituximab for treating relapsing multiple sclerosis (TA1025)
Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.
View recommendations for TA245Show all sections
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
Evidence-based recommendations on bee venom and wasp venom (Pharmalgen) for treating bee and wasp venom allergy.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.